252 related articles for article (PubMed ID: 22076476)
1. The CIRAS study: a case control study to define the clinical, immunologic, and radiographic features of aromatase inhibitor-induced musculoskeletal symptoms.
Shanmugam VK; McCloskey J; Elston B; Allison SJ; Eng-Wong J
Breast Cancer Res Treat; 2012 Jan; 131(2):699-708. PubMed ID: 22076476
[TBL] [Abstract][Full Text] [Related]
2. Sonographic and electrodiagnostic evaluations in patients with aromatase inhibitor-related arthralgia.
Dizdar O; Ozçakar L; Malas FU; Harputluoglu H; Bulut N; Aksoy S; Ozisik Y; Altundag K
J Clin Oncol; 2009 Oct; 27(30):4955-60. PubMed ID: 19752344
[TBL] [Abstract][Full Text] [Related]
3. Defining the aromatase inhibitor musculoskeletal syndrome: a prospective study.
Singer O; Cigler T; Moore AB; Levine AB; Hentel K; Belfi L; Do HT; Mandl LA
Arthritis Care Res (Hoboken); 2012 Dec; 64(12):1910-8. PubMed ID: 22730307
[TBL] [Abstract][Full Text] [Related]
4. Indications of clinical and genetic predictors for aromatase inhibitors related musculoskeletal adverse events in Chinese Han women with breast cancer.
Wang J; Lu K; Song Y; Xie L; Zhao S; Wang Y; Sun W; Liu L; Zhao H; Tang D; Ma W; Pan B; Xuan Q; Liu H; Zhang Q
PLoS One; 2013; 8(7):e68798. PubMed ID: 23894347
[TBL] [Abstract][Full Text] [Related]
5. Aromatase inhibitor-associated arthralgia syndrome.
Burstein HJ
Breast; 2007 Jun; 16(3):223-34. PubMed ID: 17368903
[TBL] [Abstract][Full Text] [Related]
6. A prospective assessment of musculoskeletal toxicity and loss of grip strength in breast cancer patients receiving adjuvant aromatase inhibitors and tamoxifen, and relation with BMI.
Lintermans A; Van Asten K; Wildiers H; Laenen A; Paridaens R; Weltens C; Verhaeghe J; Vanderschueren D; Smeets A; Van Limbergen E; Leunen K; Christiaens MR; Neven P
Breast Cancer Res Treat; 2014 Jul; 146(1):109-16. PubMed ID: 24816806
[TBL] [Abstract][Full Text] [Related]
7. Arthralgia induced by endocrine treatment for breast cancer: A prospective study of serum levels of insulin like growth factor-I, its binding protein and oestrogens.
Lintermans A; Vanderschueren D; Verhaeghe J; Van Asten K; Jans I; Van Herck E; Laenen A; Paridaens R; Billen J; Pauwels S; Vermeersch P; Wildiers H; Christiaens MR; Neven P
Eur J Cancer; 2014 Nov; 50(17):2925-31. PubMed ID: 25304297
[TBL] [Abstract][Full Text] [Related]
8. Randomized Multicenter Placebo-Controlled Trial of Omega-3 Fatty Acids for the Control of Aromatase Inhibitor-Induced Musculoskeletal Pain: SWOG S0927.
Hershman DL; Unger JM; Crew KD; Awad D; Dakhil SR; Gralow J; Greenlee H; Lew DL; Minasian LM; Till C; Wade JL; Meyskens FL; Moinpour CM
J Clin Oncol; 2015 Jun; 33(17):1910-7. PubMed ID: 25940724
[TBL] [Abstract][Full Text] [Related]
9. Pilot study of acupuncture for the treatment of joint symptoms related to adjuvant aromatase inhibitor therapy in postmenopausal breast cancer patients.
Crew KD; Capodice JL; Greenlee H; Apollo A; Jacobson JS; Raptis G; Blozie K; Sierra A; Hershman DL
J Cancer Surviv; 2007 Dec; 1(4):283-91. PubMed ID: 18648963
[TBL] [Abstract][Full Text] [Related]
10. Aromatase inhibitor-related musculoskeletal symptoms: is preventing osteoporosis the key to eliminating these symptoms?
Muslimani AA; Spiro TP; Chaudhry AA; Taylor HC; Jaiyesimi I; Daw HA
Clin Breast Cancer; 2009 Feb; 9(1):34-8. PubMed ID: 19299238
[TBL] [Abstract][Full Text] [Related]
11. A phase II study evaluating the efficacy of zoledronic acid in prevention of aromatase inhibitor-associated musculoskeletal symptoms: the ZAP trial.
Santa-Maria CA; Bardia A; Blackford AL; Snyder C; Connolly RM; Fetting JH; Hayes DF; Jeter SC; Miller RS; Nguyen A; Quinlan K; Rosner GL; Slater S; Storniolo AM; Wolff AC; Zorzi J; Henry NL; Stearns V
Breast Cancer Res Treat; 2018 Aug; 171(1):121-129. PubMed ID: 29752687
[TBL] [Abstract][Full Text] [Related]
12. Joint pain severity predicts premature discontinuation of aromatase inhibitors in breast cancer survivors.
Chim K; Xie SX; Stricker CT; Li QS; Gross R; Farrar JT; DeMichele A; Mao JJ
BMC Cancer; 2013 Sep; 13():401. PubMed ID: 24004677
[TBL] [Abstract][Full Text] [Related]
13. Aromatase Inhibitor-Associated Musculoskeletal Syndrome: Understanding Mechanisms and Management.
Hyder T; Marino CC; Ahmad S; Nasrazadani A; Brufsky AM
Front Endocrinol (Lausanne); 2021; 12():713700. PubMed ID: 34385978
[TBL] [Abstract][Full Text] [Related]
14. Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors.
Henry NL; Giles JT; Ang D; Mohan M; Dadabhoy D; Robarge J; Hayden J; Lemler S; Shahverdi K; Powers P; Li L; Flockhart D; Stearns V; Hayes DF; Storniolo AM; Clauw DJ
Breast Cancer Res Treat; 2008 Sep; 111(2):365-72. PubMed ID: 17922185
[TBL] [Abstract][Full Text] [Related]
15. Acupoint Thread Embedding Combined With Wenshen Bugu Decoction for the Treatment of Aromatase Inhibitor-Associated Musculoskeletal Symptom Among Postmenopausal Breast Cancer Patients: Study Protocol of a Randomized Controlled Trial.
Zou X; Chen ZY; Yang YH; Qiao Y; He SJ; Li Q; Chen WL; Zhang XY; Li SY; Sha SY; Hu MH; Zhang XY; Yang MJ; Wang RP; Wu HG; Shi Y; Xue XH; Ji YJ
Integr Cancer Ther; 2023; 22():15347354231188679. PubMed ID: 37565358
[TBL] [Abstract][Full Text] [Related]
16. Hypovitaminosis D is a predictor of aromatase inhibitor musculoskeletal symptoms.
Singer O; Cigler T; Moore AB; Levine AB; Do HT; Mandl LA
Breast J; 2014; 20(2):174-9. PubMed ID: 24467395
[TBL] [Abstract][Full Text] [Related]
17. Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome.
Morales L; Pans S; Verschueren K; Van Calster B; Paridaens R; Westhovens R; Timmerman D; De Smet L; Vergote I; Christiaens MR; Neven P
J Clin Oncol; 2008 Jul; 26(19):3147-52. PubMed ID: 18474874
[TBL] [Abstract][Full Text] [Related]
18. Impact of chemotherapy on symptoms and symptom clusters in postmenopausal women with breast cancer prior to aromatase inhibitor therapy.
Li H; Sereika SM; Marsland AL; Conley YP; Bender CM
J Clin Nurs; 2019 Dec; 28(23-24):4560-4571. PubMed ID: 31469461
[TBL] [Abstract][Full Text] [Related]
19. Incidence of menopausal symptoms in postmenopausal breast cancer patients treated with aromatase inhibitors.
Hong D; Bi L; Zhou J; Tong Y; Zhao Q; Chen J; Lu X
Oncotarget; 2017 Jun; 8(25):40558-40567. PubMed ID: 28489562
[TBL] [Abstract][Full Text] [Related]
20. Prospective evaluation of finger two-point discrimination and carpal tunnel syndrome among women with breast cancer receiving adjuvant aromatase inhibitor therapy.
Sheng JY; Blackford AL; Bardia A; Venkat R; Rosson G; Giles J; Hayes DF; Jeter SC; Zhang Z; Hayden J; Nguyen A; Storniolo AM; Tarpinian K; Henry NL; Stearns V
Breast Cancer Res Treat; 2019 Aug; 176(3):617-624. PubMed ID: 31079282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]